Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 159

1.

Analysis of modification and proteolytic targeting by the ubiquitin-like modifier FAT10.

Aichem A, Boehm AN, Catone N, Schmidtke G, Groettrup M.

Methods Enzymol. 2019;618:229-256. doi: 10.1016/bs.mie.2018.12.040. Epub 2019 Feb 8.

PMID:
30850054
2.

The ubiquitin-like modifier FAT10 is required for normal IFN-γ production by activated CD8+ T cells.

Mah MM, Basler M, Groettrup M.

Mol Immunol. 2019 Apr;108:111-120. doi: 10.1016/j.molimm.2019.02.010. Epub 2019 Feb 25.

PMID:
30818228
3.

The ubiquitin-like modifier FAT10 stimulates the activity of deubiquitylating enzyme OTUB1.

Bialas J, Boehm AN, Catone N, Aichem A, Groettrup M.

J Biol Chem. 2019 Mar 22;294(12):4315-4330. doi: 10.1074/jbc.RA118.005406. Epub 2019 Feb 4.

PMID:
30718280
4.

Immunoproteasome inhibition induces plasma cell apoptosis and preserves kidney allografts by activating the unfolded protein response and suppressing plasma cell survival factors.

Li J, Koerner J, Basler M, Brunner T, Kirk CJ, Groettrup M.

Kidney Int. 2019 Mar;95(3):611-623. doi: 10.1016/j.kint.2018.10.022. Epub 2019 Jan 23.

PMID:
30685098
5.

Immunoproteasome Inhibition Impairs T and B Cell Activation by Restraining ERK Signaling and Proteostasis.

Schmidt C, Berger T, Groettrup M, Basler M.

Front Immunol. 2018 Oct 26;9:2386. doi: 10.3389/fimmu.2018.02386. eCollection 2018.

6.

Prevention of neuronal apoptosis by astrocytes through thiol-mediated stress response modulation and accelerated recovery from proteotoxic stress.

Gutbier S, Spreng AS, Delp J, Schildknecht S, Karreman C, Suciu I, Brunner T, Groettrup M, Leist M.

Cell Death Differ. 2018 Dec;25(12):2101-2117. doi: 10.1038/s41418-018-0229-x. Epub 2018 Nov 2.

7.

Author Correction: The structure of the ubiquitin-like modifier FAT10 reveals an alternative targeting mechanism for proteasomal degradation.

Aichem A, Anders S, Catone N, Rößler P, Stotz S, Berg A, Schwab R, Scheuermann S, Bialas J, Schütz-Stoffregen MC, Schmidtke G, Peter C, Groettrup M, Wiesner S.

Nat Commun. 2018 Nov 2;9(1):4646. doi: 10.1038/s41467-018-07183-0.

8.

Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity.

Basler M, Lindstrom MM, LaStant JJ, Bradshaw JM, Owens TD, Schmidt C, Maurits E, Tsu C, Overkleeft HS, Kirk CJ, Langrish CL, Groettrup M.

EMBO Rep. 2018 Dec;19(12). pii: e46512. doi: 10.15252/embr.201846512. Epub 2018 Oct 2.

PMID:
30279279
9.

On the role of the immunoproteasome in transplant rejection.

Basler M, Li J, Groettrup M.

Immunogenetics. 2019 Mar;71(3):263-271. doi: 10.1007/s00251-018-1084-0. Epub 2018 Sep 15. Review.

PMID:
30220008
10.

The structure of the ubiquitin-like modifier FAT10 reveals an alternative targeting mechanism for proteasomal degradation.

Aichem A, Anders S, Catone N, Rößler P, Stotz S, Berg A, Schwab R, Scheuermann S, Bialas J, Schütz-Stoffregen MC, Schmidtke G, Peter C, Groettrup M, Wiesner S.

Nat Commun. 2018 Aug 20;9(1):3321. doi: 10.1038/s41467-018-05776-3. Erratum in: Nat Commun. 2018 Nov 2;9(1):4646.

11.

Defective immuno- and thymoproteasome assembly causes severe immunodeficiency.

Treise I, Huber EM, Klein-Rodewald T, Heinemeyer W, Grassmann SA, Basler M, Adler T, Rathkolb B, Helming L, Andres C, Klaften M, Landbrecht C, Wieland T, Strom TM, McCoy KD, Macpherson AJ, Wolf E, Groettrup M, Ollert M, Neff F, Gailus-Durner V, Fuchs H, Hrabě de Angelis M, Groll M, Busch DH.

Sci Rep. 2018 Apr 13;8(1):5975. doi: 10.1038/s41598-018-24199-0.

12.

The expression profile of the ubiquitin-like modifier FAT10 in immune cells suggests cell type-specific functions.

Schregle R, Mah MM, Mueller S, Aichem A, Basler M, Groettrup M.

Immunogenetics. 2018 Jul;70(7):429-438. doi: 10.1007/s00251-018-1055-5. Epub 2018 Mar 5.

PMID:
29508036
13.

Immunoproteasome inhibition prevents chronic antibody-mediated allograft rejection in renal transplantation.

Li J, Basler M, Alvarez G, Brunner T, Kirk CJ, Groettrup M.

Kidney Int. 2018 Mar;93(3):670-680. doi: 10.1016/j.kint.2017.09.023. Epub 2017 Dec 8.

PMID:
29229189
14.

The 20S immunoproteasome and constitutive proteasome bind with the same affinity to PA28αβ and equally degrade FAT10.

Schmidtke G, Schregle R, Alvarez G, Huber EM, Groettrup M.

Mol Immunol. 2017 Dec 2. pii: S0161-5890(17)30593-X. doi: 10.1016/j.molimm.2017.11.030. [Epub ahead of print]

PMID:
29208314
15.

The immunoproteasome subunit LMP7 is required in the murine thymus for filling up a hole in the T cell repertoire.

Basler M, Mundt S, Groettrup M.

Eur J Immunol. 2018 Mar;48(3):419-429. doi: 10.1002/eji.201747282. Epub 2017 Nov 10.

16.

Amelioration of autoimmunity with an inhibitor selectively targeting all active centres of the immunoproteasome.

Basler M, Maurits E, de Bruin G, Koerner J, Overkleeft HS, Groettrup M.

Br J Pharmacol. 2018 Jan;175(1):38-52. doi: 10.1111/bph.14069. Epub 2017 Nov 29.

17.

Inhibition and deficiency of the immunoproteasome subunit LMP7 suppress the development and progression of colorectal carcinoma in mice.

Koerner J, Brunner T, Groettrup M.

Oncotarget. 2017 Feb 7;8(31):50873-50888. doi: 10.18632/oncotarget.15141. eCollection 2017 Aug 1.

18.

No prolongation of skin allograft survival by immunoproteasome inhibition in mice.

Mundt S, Basler M, Sawitzki B, Groettrup M.

Mol Immunol. 2017 Aug;88:32-37. doi: 10.1016/j.molimm.2017.05.022. Epub 2017 Jun 2.

PMID:
28582644
19.

Chronic stress suppresses anti-tumor TCD8+ responses and tumor regression following cancer immunotherapy in a mouse model of melanoma.

Sommershof A, Scheuermann L, Koerner J, Groettrup M.

Brain Behav Immun. 2017 Oct;65:140-149. doi: 10.1016/j.bbi.2017.04.021. Epub 2017 Apr 27.

PMID:
28457810
20.

Immunoproteasome subunit deficiency has no influence on the canonical pathway of NF-κB activation.

Bitzer A, Basler M, Krappmann D, Groettrup M.

Mol Immunol. 2017 Mar;83:147-153. doi: 10.1016/j.molimm.2017.01.019. Epub 2017 Jan 31.

PMID:
28157553
21.

Newly translated proteins are substrates for ubiquitin, ISG15, and FAT10.

Spinnenhirn V, Bitzer A, Aichem A, Groettrup M.

FEBS Lett. 2017 Jan;591(1):186-195. doi: 10.1002/1873-3468.12512. Epub 2016 Dec 20.

22.

Analyzing structure-function relationships of artificial and cancer-associated PARP1 variants by reconstituting TALEN-generated HeLa PARP1 knock-out cells.

Rank L, Veith S, Gwosch EC, Demgenski J, Ganz M, Jongmans MC, Vogel C, Fischbach A, Buerger S, Fischer JM, Zubel T, Stier A, Renner C, Schmalz M, Beneke S, Groettrup M, Kuiper RP, Bürkle A, Ferrando-May E, Mangerich A.

Nucleic Acids Res. 2016 Dec 1;44(21):10386-10405. Epub 2016 Sep 29.

23.

The ubiquitin-like modifier FAT10 in cancer development.

Aichem A, Groettrup M.

Int J Biochem Cell Biol. 2016 Oct;79:451-461. doi: 10.1016/j.biocel.2016.07.001. Epub 2016 Jul 5. Review.

PMID:
27393295
24.

A cascading activity-based probe sequentially targets E1-E2-E3 ubiquitin enzymes.

Mulder MP, Witting K, Berlin I, Pruneda JN, Wu KP, Chang JG, Merkx R, Bialas J, Groettrup M, Vertegaal AC, Schulman BA, Komander D, Neefjes J, El Oualid F, Ovaa H.

Nat Chem Biol. 2016 Jul;12(7):523-30. doi: 10.1038/nchembio.2084. Epub 2016 May 16.

25.

Inhibiting the immunoproteasome exacerbates the pathogenesis of systemic Candida albicans infection in mice.

Mundt S, Basler M, Buerger S, Engler H, Groettrup M.

Sci Rep. 2016 Jan 18;6:19434. doi: 10.1038/srep19434.

26.

The STEAP1(262-270) peptide encapsulated into PLGA microspheres elicits strong cytotoxic T cell immunity in HLA-A*0201 transgenic mice--A new approach to immunotherapy against prostate carcinoma.

Herrmann VL, Wieland DE, Legler DF, Wittmann V, Groettrup M.

Prostate. 2016 Apr;76(5):456-68. doi: 10.1002/pros.23136. Epub 2015 Dec 30.

PMID:
26715028
27.

Chaperone BAG6 is dispensable for MHC class I antigen processing and presentation.

Bitzer A, Basler M, Groettrup M.

Mol Immunol. 2016 Jan;69:99-105. doi: 10.1016/j.molimm.2015.11.004. Epub 2015 Nov 17.

PMID:
26598275
28.

Inhibition and deficiency of the immunoproteasome subunit LMP7 attenuates LCMV-induced meningitis.

Mundt S, Engelhardt B, Kirk CJ, Groettrup M, Basler M.

Eur J Immunol. 2016 Jan;46(1):104-13. doi: 10.1002/eji.201545578. Epub 2015 Nov 2.

29.

The immunoproteasome: a novel drug target for autoimmune diseases.

Basler M, Mundt S, Bitzer A, Schmidt C, Groettrup M.

Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 92):S74-9. Epub 2015 Oct 12. Review.

PMID:
26458097
30.

The Ubiquitin-like Modifier FAT10 Is Selectively Expressed in Medullary Thymic Epithelial Cells and Modifies T Cell Selection.

Buerger S, Herrmann VL, Mundt S, Trautwein N, Groettrup M, Basler M.

J Immunol. 2015 Nov 1;195(9):4106-16. doi: 10.4049/jimmunol.1500592. Epub 2015 Sep 23.

31.

Cytotoxic T cell vaccination with PLGA microspheres interferes with influenza A virus replication in the lung and suppresses the infectious disease.

Herrmann VL, Hartmayer C, Planz O, Groettrup M.

J Control Release. 2015 Oct 28;216:121-31. doi: 10.1016/j.jconrel.2015.08.019. Epub 2015 Aug 12.

PMID:
26276509
32.

The ubiquitin-specific protease USP8 is critical for the development and homeostasis of T cells.

Dufner A, Kisser A, Niendorf S, Basters A, Reissig S, Schönle A, Aichem A, Kurz T, Schlosser A, Yablonski D, Groettrup M, Buch T, Waisman A, Schamel WW, Prinz M, Knobeloch KP.

Nat Immunol. 2015 Sep;16(9):950-60. doi: 10.1038/ni.3230. Epub 2015 Jul 27.

PMID:
26214742
33.

The ubiquitin-like modifier FAT10 in antigen processing and antimicrobial defense.

Basler M, Buerger S, Groettrup M.

Mol Immunol. 2015 Dec;68(2 Pt A):129-32. doi: 10.1016/j.molimm.2015.04.012. Epub 2015 May 14. Review.

PMID:
25983082
34.

Analgesia in mice with experimental meningitis reduces pain without altering immune parameters.

Mundt S, Groettrup M, Basler M.

ALTEX. 2015;32(3):183-9. doi: 10.14573/altex.1502021. Epub 2015 Mar 24.

35.

Conjugation of the ubiquitin activating enzyme UBE1 with the ubiquitin-like modifier FAT10 targets it for proteasomal degradation.

Bialas J, Groettrup M, Aichem A.

PLoS One. 2015 Mar 13;10(3):e0120329. doi: 10.1371/journal.pone.0120329. eCollection 2015.

36.

Editorial overview: Molecular immunology: targeting the immune system.

Groettrup M, Ovaa H.

Curr Opin Chem Biol. 2014 Dec;23:v-vii. No abstract available.

PMID:
25467126
37.

No evidence for immunoproteasomes in chicken lymphoid organs and activated lymphocytes.

Erath S, Groettrup M.

Immunogenetics. 2015 Jan;67(1):51-60. doi: 10.1007/s00251-014-0814-1. Epub 2014 Nov 19.

PMID:
25403261
38.

The ubiquitin-like modifier FAT10 decorates autophagy-targeted Salmonella and contributes to Salmonella resistance in mice.

Spinnenhirn V, Farhan H, Basler M, Aichem A, Canaan A, Groettrup M.

J Cell Sci. 2014 Nov 15;127(Pt 22):4883-93. doi: 10.1242/jcs.152371. Epub 2014 Sep 30.

39.

Subunit specific inhibitors of proteasomes and their potential for immunomodulation.

Kisselev AF, Groettrup M.

Curr Opin Chem Biol. 2014 Dec;23:16-22. doi: 10.1016/j.cbpa.2014.08.012. Epub 2014 Sep 15. Review.

40.

The effect of trauma-focused therapy on the altered T cell distribution in individuals with PTSD: evidence from a randomized controlled trial.

Morath J, Gola H, Sommershof A, Hamuni G, Kolassa S, Catani C, Adenauer H, Ruf-Leuschner M, Schauer M, Elbert T, Groettrup M, Kolassa IT.

J Psychiatr Res. 2014 Jul;54:1-10. doi: 10.1016/j.jpsychires.2014.03.016. Epub 2014 Mar 27.

PMID:
24726027
41.

Investigations into the auto-FAT10ylation of the bispecific E2 conjugating enzyme UBA6-specific E2 enzyme 1.

Aichem A, Catone N, Groettrup M.

FEBS J. 2014 Apr;281(7):1848-59. doi: 10.1111/febs.12745. Epub 2014 Mar 3.

42.

Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis.

Basler M, Mundt S, Muchamuel T, Moll C, Jiang J, Groettrup M, Kirk CJ.

EMBO Mol Med. 2014 Feb;6(2):226-38. doi: 10.1002/emmm.201303543. Epub 2014 Jan 16.

43.

The unique functions of tissue-specific proteasomes.

Kniepert A, Groettrup M.

Trends Biochem Sci. 2014 Jan;39(1):17-24. doi: 10.1016/j.tibs.2013.10.004. Epub 2013 Nov 26. Review.

PMID:
24286712
44.

Immuno- and constitutive proteasomes do not differ in their abilities to degrade ubiquitinated proteins.

Nathan JA, Spinnenhirn V, Schmidtke G, Basler M, Groettrup M, Goldberg AL.

Cell. 2013 Feb 28;152(5):1184-94. doi: 10.1016/j.cell.2013.01.037.

45.

Posttraumatic stress disorder is associated with an enhanced spontaneous production of pro-inflammatory cytokines by peripheral blood mononuclear cells.

Gola H, Engler H, Sommershof A, Adenauer H, Kolassa S, Schedlowski M, Groettrup M, Elbert T, Kolassa IT.

BMC Psychiatry. 2013 Jan 29;13:40. doi: 10.1186/1471-244X-13-40.

46.

FAT10ylation as a signal for proteasomal degradation.

Schmidtke G, Aichem A, Groettrup M.

Biochim Biophys Acta. 2014 Jan;1843(1):97-102. doi: 10.1016/j.bbamcr.2013.01.009. Epub 2013 Jan 18. Review.

47.

Using protease inhibitors in antigen presentation assays.

Basler M, Groettrup M.

Methods Mol Biol. 2013;960:31-39. doi: 10.1007/978-1-62703-218-6_3.

PMID:
23329476
48.

The immunoproteasome in antigen processing and other immunological functions.

Basler M, Kirk CJ, Groettrup M.

Curr Opin Immunol. 2013 Feb;25(1):74-80. doi: 10.1016/j.coi.2012.11.004. Epub 2012 Dec 6. Review.

PMID:
23219269
49.

Endosomal trafficking of open Major Histocompatibility Class I conformers--implications for presentation of endocytosed antigens.

Mahmutefendić H, Zagorac GB, Tomaš MI, Groettrup M, Momburg F, Lučin P.

Mol Immunol. 2013 Sep;55(2):149-52. doi: 10.1016/j.molimm.2012.10.008. Epub 2012 Nov 27. Review.

PMID:
23200229
50.

Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation.

Kalim KW, Basler M, Kirk CJ, Groettrup M.

J Immunol. 2012 Oct 15;189(8):4182-93. doi: 10.4049/jimmunol.1201183. Epub 2012 Sep 14.

Supplemental Content

Loading ...
Support Center